Autres langues Matinas BioPharma Holdings, Inc.

Actions

MTNB

US5768101058

Temps réel estimé Cboe BZX Autres places de cotation 21:55:43 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,179 ^USD	-1,38 %		-2,56 %	-15,40 %

27/03	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
27/03	Matinas BioPharma Holdings, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	25/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	25/03
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25/03
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25/03
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	25/03
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response	22/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	22/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	22/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate, Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	27/02
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	26/02
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	26/02
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	26/02
Matinas Reaches Agreement With FDA For Late-Stage Invasive Aspergillosis Trial	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Matinas BioPharma Holdings, Inc.

Actions

MTNB

US5768101058

Autres langues

Filtres